By Bhanvi Satija LONDON, May 28 (Reuters) - GSK said its experimental chronic hepatitis B drug helped nearly one in five ...

Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these ...

In about 20% of the drug's recipients, the virus remained undetectable for at least six months after all treatments were ...

Chronic hepatitis B virus (HBV)-infected patients may exhibit liver fibrosis and other pathological changes despite normal alanine aminotransferase (ALT). This study aimed to assess the efficacy and ...

An experimental GSK drug in development for treating chronic hepatitis B now has results from two pivotal studies showing the therapy brought levels of the virus low enough to allow the immune system ...

—In a global study of 614 adults with chronic hepatitis B (CHB), treatment compliance was affected by obstacles such as physical functioning and healthcare service accessibility, making clear the need ...

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This ...

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping ...